Richard Rogers Email & Phone Number

Seattle, WA, US

Lawrence Township, NJ, US

Seattle, WA, US

At Juno Therapeutics, I lead a team that is involved in the bioanalytical characterization of CAR-T cell therapies. We apply state of the art analytical tools, including mass spectrometry, to understand the process involved in making CAR-T cell therapies. I am also the analytical lead for two pipeline programs that are in a phase 1 clinical trial.

Seattle, WA, US

My group uses the MAM to support every aspect of process development. MAM data is utilized from molecular optimization through formulation devlopment. I lead the MAM Consortium. The purpose of the consortium is to enable the BioPharma community to implement a robust mass spec based method for biotherapeutic characterization and release of biotherapeutics.

Seattle, WA, US

At Just, I will develop mass spectrometry techniques to quickly characterize biotherapeutics. We will use this mass spectrometry platform for real-time monitoring of product quality attributes and release of biotherapeutics.

Thousand Oaks, CA, US

• I developed a 1-D nano-spray LC/MS method for detecting host cell proteins in drug substance. This method is faster and the data are more comprehensive than other techniques used to detect host cell proteins.
• I lead a team that has developed a method that integrates a MS-based multi-attribute method (MAM) into a fully compliant package required for quality control and release testing of biologics in a regulated environment.
• I developed and tested the qualification experiments necessary for implementation of the MAM.
• I co-developed a non-reduced MAM that has automated the characterization and quantification of disulfide isoforms for monoclonal antibodies.

Seattle, Washington, US

• Characterizing the role of protein ISGylation during Mycobacterium tuberculosis infection.
• Identified more than 1300 putative ISG15 targets in bone marrow macrophages using mass spectrometry.
• Examining the effect of SUMO modification on transcription factors involved in the innate immune system.
• Managing a project to characterize the phospho-proteome of bone marrow macrophages stimulated with LPS.

• Developed Theraclone’s SOP for target identification of human antibodies rescued from human germinal centers.
• Identified the target of the antibody that secured Theraclone’s series B round of funding.
• Developed a bead based assay to screen B-cell supernatants for specific antibodies.

Seattle, Washington, US

• Catalogued the murine proteome using organelle isolation and mass spectrometry.
• Examined the differences in the posttranslational modification profile of red blood cell membrane proteins when mice are treated with different drugs using mass spectrometry.
• Optimized HPLC techniques to separate peptides and proteins to obtain better coverage of samples analyzed by mass spectrometry.

Seattle, Washington, US

• Developed software to predict location of posttranslational modification of proteins using mass spectrometry. Optimized conditions for both yeast and mammalian systems.
• Developed techniques to quickly isolate posttranslationally modified proteins by affinity chromatography.
• Examined the effect of ubiquitin mediated protein degradation on peroxisome biogenesis using yeast as a model organism.
• Optimized techniques to map binding domains responsible for protein-protein interactions using in vitro translated proteins.
• Demonstrated that the yeast nuclear pore complex is involved in maintaining chromatin boundaries using genetic techniques.

Baltimore, MD, US

• Developed and optimized an in vitro posttranslational modification system for determining the site and efficiency of SUMO modifying proteins. Purification of all enzymes and substrates was necessary for this assay.
• First to demonstrate that SUMO modification of STAT1 affected its response to interferon-gamma.
• First to show that SUMO modification of the heat shock proteins HSF1 and HSF2 affects their ability to bind DNA.
• Using immunofluorescence, demonstrated that SUMO modified proteins localize to the XY body of pachytene spermatocytes.

Tacoma, WA, US

• Examined the effect of the Thrombospondin proteins on angiogenesis using cell culture to demonstrated that type I repeats are responsible for anti-angiogenic activity of Thrombospondin 1

Ph.D; Department, Biochemistry And Molecular Biology

B.S; Honors, Chemistry